Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases
Michele Bottosso(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), Fabio Girardi(London School of Hygiene & Tropical Medicine), Grazia Maria Vernaci(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Vittoria Aldegheri(Istituto Oncologico Veneto), William Jacot(Inserm), Léa Sinoquet(Université de Montpellier), Maria Cristina Guarascio(University of Padua), Caterina Barbieri(Vita-Salute San Raffaele University), Amélie Darlix(Institut de Recherche en Cancérologie de Montpellier), Gaia Griguolo(University of North Carolina at Chapel Hill), Federica Miglietta(University of Padua)
Cited by 6
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830